Preliminary findings show no benefits of Remdesivir, Hydroxychloroquine for COVID-19

Editado por Ed Newman
2020-04-28 12:27:18

Pinterest
Telegram
Linkedin
WhatsApp

New York, April 28 (RHC)-- A draft manuscript of a report from a long-awaited clinical trial in China finds the antiviral drug remdesivir failed to lower the death rates or recovery times of COVID-19 patients.  The findings have not yet passed peer review. 

Preliminary results of a study by the New York state Department of Health showed the drug touted by President Trump as a curative for COVID-19 — hydroxychloroquine — had no effect on patients’ recoveries.



Comentários


Deixe um comentário
Todos os campos são requeridos
Não será publicado
captcha challenge
up